DelveInsight’s “Hypoxic Ischemic Encephalopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hypoxic Ischemic Encephalopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hypoxic Ischemic Encephalopathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hypoxic Ischemic Encephalopathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hypoxic Ischemic Encephalopathy: An Overview
Hypoxic-ischemic encephalopathy (HIE) is a serious and life-threatening type of newborn brain damage (brain dysfunction) that occurs when the brain doesn’t receive enough oxygen and blood flow for a period of time. As the name suggests, Hypoxic means, not enough oxygen; ischemic means not enough blood flow; and encephalopathy means brain disorder.
Neonatal encephalopathy (NE) “umbrella” term and HIE and NE are mostly used interchangeably in the literature. Other terms used for Hypoxic Ischemic Encephalopathy include birth asphyxia, perinatal asphyxia, and neonatal encephalopathy. There are three levels of Hypoxic Ischemic Encephalopathy: mild, moderate, and severe.
As per WHO, the three major causes of neonatal deaths worldwide are infections (36%, which includes sepsis/pneumonia, tetanus, and diarrhea), pre-term (28%), and birth asphyxia (23%).
Hypoxic Ischemic Encephalopathy symptoms immediately after birth will vary significantly, often depending on the severity and extent of the brain injury, as well as the areas of the brain that were affected. Babies with Hypoxic Ischemic Encephalopathy may exhibit any of the following signs: Missing reflexes, breathing problems, feeding problems, Low or high muscle tone, Seizures, Show signs of organ dysfunction, especially of the heart, lungs, kidneys, liver, and blood.
Apart from being life-threatening, Hypoxic Ischemic Encephalopathy also causes permanent brain damage. Somewhere between 15-20% of newborns diagnosed with Hypoxic Ischemic Encephalopathy will die in the first week. Some children will experience no health issues or only mild or moderate effects from Hypoxic Ischemic Encephalopathy, while others have much more severe and permanent disability, such as developmental delay; cerebral palsy (motor impairment); epilepsy; or cognitive impairment.
It is vital to note that there is currently no approved treatment option for Hypoxic Ischemic Encephalopathy. Hypoxic Ischemic Encephalopathy is mainly managed using a treatment called therapeutic hypothermia, where the baby’s brain or body is cooled down below normal temperatures to slow the cascade effect that causes widespread damage.
Hypoxic Ischemic Encephalopathy Market Key Facts
-
As per the HIE Help Center, Neonatal HIE is estimated to occur in about 1.5 per 1,000 live births. Among infants with moderate HIE, 10-20% develop minor neurological conditions, and 30-50% develop more serious complications. For infants with severe Hypoxic Ischemic Encephalopathy, there is a 25-50% mortality rate. Deaths most often occur in the first few days after birth. Of babies that survive, roughly 80% develop serious complications.
-
In a population-based study from January 2010 to December 2017 by Hage et al. (2021), 5201 babies with a diagnosis of Hypoxic Ischemic Encephalopathy received TH or died; annual numbers increased over the study period. It was concluded that treatment with TH for Hypoxic Ischemic Encephalopathy has increased in England, Scotland, and Wales. An increasing proportion of treated infants have a diagnosis of mild Hypoxic Ischemic Encephalopathy or have less severe clinical markers of hypoxia.
-
Neonatal encephalopathy due to birth asphyxia and trauma is the second leading cause of death in the first month of a child’s life. Close to half a million newborns died due to this condition in 2017.
Hypoxic Ischemic Encephalopathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hypoxic Ischemic Encephalopathy pipeline therapies. It also thoroughly assesses the Hypoxic Ischemic Encephalopathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hypoxic Ischemic Encephalopathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hypoxic Ischemic Encephalopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hypoxic Ischemic Encephalopathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hypoxic Ischemic Encephalopathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hypoxic Ischemic Encephalopathy Epidemiology, Segmented as –
-
Total Incident Cases of Hypoxic Ischemic Encephalopathy in the 7MM [2019–2032]
-
Total Diagnosed Cases of Hypoxic Ischemic Encephalopathy in the 7MM [2019–2032]
-
Total Treated Cases of Hypoxic Ischemic Encephalopathy in the 7MM [2019–2032]
-
Total Incident cases of Hypoxic Ischemic Encephalopathy segmented by severity in the 7MM [2019-2032]
Hypoxic Ischemic Encephalopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hypoxic Ischemic Encephalopathy market or expected to be launched during the study period. The analysis covers the Hypoxic Ischemic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hypoxic Ischemic Encephalopathy drugs based on their sale and market share.
The report also covers the Hypoxic Ischemic Encephalopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hypoxic Ischemic Encephalopathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hypoxic Ischemic Encephalopathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market
Hypoxic Ischemic Encephalopathy Therapeutics Analysis
Despite a multitude of studies, the ultimate pathogenesis of Hypoxic Ischemic Encephalopathy remains unknown. Hypoxic Ischemic Encephalopathy symptoms can be ambiguous and frequently overlap with other neurologic and metabolic disorders in newborns. Therefore, it is imperative to rule out life-threatening or treatable causes of these symptoms. Treatment can be separated into immediate/hospital management and long-term treatment. In moderate to severe Hypoxic Ischemic Encephalopathy, it is very important that the child is properly monitored and treated. Effective medical care may significantly reduce the child’s prognosis. The first several weeks are the most critical period for monitoring and treating a child with moderate to severe Hypoxic Ischemic Encephalopathy.
At present, there is no true cure for Hypoxic Ischemic Encephalopathy. However, currently, there is one treatment, called therapeutic hypothermia, that can reduce the extent of permanent brain damage if given very shortly after birth or the oxygen-depriving incident. Most guidelines dictate that therapeutic hypothermia be given within six hours, although there may be some benefits up to 24 hours. Babies with severe Hypoxic Ischemic Encephalopathy injuries will often need life-long support and accommodations.
Hypoxic Ischemic Encephalopathy Companies Actively Working in the Therapeutics Market Include
-
ReAlta Life Sciences
-
Hope Biosciences
-
GW Pharmaceuticals (acquired by Jazz Pharmaceuticals)
And Many Others
Emerging and Marketed Hypoxic Ischemic Encephalopathy Therapies Covered in the Report Include:
-
RLS-0071: ReAlta Life Sciences
-
HB-adMSCs: Hope Biosciences
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hypoxic Ischemic Encephalopathy Competitive Intelligence Analysis
4. Hypoxic Ischemic Encephalopathy Market Overview at a Glance
5. Hypoxic Ischemic Encephalopathy Disease Background and Overview
6. Hypoxic Ischemic Encephalopathy Patient Journey
7. Hypoxic Ischemic Encephalopathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hypoxic Ischemic Encephalopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoxic Ischemic Encephalopathy Unmet Needs
10. Key Endpoints of Hypoxic Ischemic Encephalopathy Treatment
11. Hypoxic Ischemic Encephalopathy Marketed Therapies
12. Hypoxic Ischemic Encephalopathy Emerging Drugs and Latest Therapeutic Advances
13. Hypoxic Ischemic Encephalopathy Seven Major Market Analysis
14. Attribute Analysis
15. Hypoxic Ischemic Encephalopathy Market Outlook (In US, EU5, and Japan)
16. Hypoxic Ischemic Encephalopathy Companies Active in the Market
17. Hypoxic Ischemic Encephalopathy Access and Reimbursement Overview
18. KOL Views on the Hypoxic Ischemic Encephalopathy Market
19. Hypoxic Ischemic Encephalopathy Market Drivers
20. Hypoxic Ischemic Encephalopathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Acute Lymphoblastic Leukemia Market
“Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Acute Lymphoblastic Leukemia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices